Clinical Trials Browser

Phase 1/2 × CPX-351 × 30 days × Clear all

NCT04049539 2026-04-08

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute